ICanWin CAMPAIGN

ICanWin INTENDS TOProcure cutting edge treatments from appropriate partners and distribute these treatments to people in need across the globe, particularly in areas that are not commonly considered primary markets for these partners.

Bring hope and the chance for a better life to patients who are out of all other options, or for other reasons don’t have access to such treatments.

Perform and support research and educational efforts aimed toward promoting advancement of new medical discoveries that have the potential to help those in need.

CLINICAL SITESICanWin has partnered with clinical sites in Europe, South America, China, and the Caribbean to provide expanded access of novel therapies to local patients on a compassionate-care basis, all in accordance with local legal and regulatory requirements.

PARTNERSHIPImmunophotonics has stepped up as the first partner in this effort – donating product, time and energy to launching ICanWin. After a successful first partnership, ICanWin will expand by creating new relationships with other partners, and expanding this model to accelerate research and treatments worldwide.

CATALYST ICanWin will partner with life-science companies, like Immunophotonics, to bring innovative technologies to those who need it most. In order to deliver on this promise, ICanWin will also form partnerships with medical providers, such as physicians and clinics, and keep patients fully informed about the program. The long-term vision is to have multiple life-science companies donate experimental, investigational clinical-grade materials to ICanWin, for the purpose of trying to help patients for whom all other options have failed.

ICanWin is a U.S. nonprofit organization that was founded with the purpose of expanding access to modern, investigational, and/or developing therapies for indications with high morbidity, such as cancer and related diseases, to patients worldwide without other available treatment options and who otherwise don’t have access to such therapies.

Funding from the ICanWin campaign will support the infrastructure necessary to ensure these steps can be conducted in a compliant and safe manner. Staff will be hired, and the organization will purchase the techno-logical infrastructure essential to data management.

ST

HIRESTAFF

$60,000

INFORMATIONMANAGEMENT

$15,000

OFFICE& TRAVEL

$15,000

COST

S

FUND

ING

Uganda

Peru

Bahamas Philippines

China

ICanWin

Sweden & Germany

EXISTING SITES

POTENTIAL SITE

PATIENTCARE

$100,000

LIFE-SCIENCECOMPANIES

PATIENTS FOR WHOMALL OTHER OPTIONS FAILED

MEDICALPROVIDERS

This campaign is inspired by a stage-four cancer patient who participated in a clinicial trial on a compassionate-care basis. She now runs an early-childhood education program in Peru. Her story inspires us, and we would like to donate $10,000 to her program. See her story at ICanWin.org.10K

ICanWin is headquartered in St. Louis

Immunophotonics is a biotech company developing a proprietary drug for use in a minimally invasive therapeutic cancer vaccine (inCVAX) for the treatment of metastatic tumors. While additional clinical trials are necessary for the potential treatment, to further assess the safety and efficacy, first-in-human clinical trial results have been encouraging.

inCVAX at a GlanceINVESTIGATING A 6 STEP SUMMARY

The second step of the actual treatment would be to inject GC into the same tumor where the laser was applied. The purpose of the injection of GC is to potentially activate antigen presenting cells (APCs), such as dendritic cells, so that the APCs

interact with the tumor antigens released by

laser-heating, and for a systemic anti-tumor

T-cell response to be induced.

The matured T-cells should now migrate throughout the body, and begin infiltrating tumors that are now recognized as foreign.

The final step of the inCVAX process is that cytotoxic T-cells may attack and destroy tumor cells systemically, which may lead to shrinkage or elimination of solid tumors throughout the body.

Once the actual treatment is concluded (Steps 1 & 2), the activated antigen presenting cells (APCs) should interact with the heat-killed tumor cells, and begin processing whole cell tumor antigens. We hypothesize that GC helps facilitate the uptake of tumor antigens into the activated APCs, such as dendritic cells.

The proposed inCVAX approach is composed of the following:1) Local heating via thermal laser of one (or more) selected tumor(s) which causes local tumor destruction and release of tumor antigens. 2) Local administration of our proprietary compound (GC) to elicit a specific immune response against the tumor antigens that were released by the action of the laser.

inCVAX is an investigational procedure that uses a local intervention intended to induce a system-

wide anti-tumor response. In other words, inCVAX is being developed as a two-injection

procedure, into any one tumor, that is intended to educate the body’s immune

system to recognize the cancer as foreign and eliminate the cancer

wherever it might be in the body.

Once the antigen presenting cells have phagocytosed tumor cell debris and initiated processing of tumor antigens, the APC should migrate to lymph nodes, and present the tumor antigens to immature T-cells. As a response to antigen presentation, the T-cells may mature and may initiate proliferation to build a defense against tumor cells.

Tumor/Metastasis

Lymphnode

TumorShrinkage Laser-accesible

Tumor/Metastasis

Tumor/Metastasis

For illustrationpurposes only.

The first step of inCVAX would be to

target any one (or multiple) tumor(s) with a

thermal laser to induce local tumor destruction and to release (whole cell) tumor antigens.

The procedure is practical: 1) Optical fiber would be injected

(guided by a needle) into any accessible tumor.

2) The laser is switched on and applied for 10 minutes.

3) Optical fiber is removed.

501(c)(3) NonprofitGOAL: $200,000

Donations fund start-up costs:Information management software

First staff person (executive director)Therapy administration expenses

(physicians, hospital stays, travel, etc.)

Patient treatment is first approved by the appropriate reviewing body in that country. The investigational therapies are then provided to patients for whom all other options have failed.

“The inCVAX compassionate use program is for patients for who are not eligible for additional conventional treatments. This potential cancer vaccine is minimally invasive, and based on early findings, may allow patients to return to normal daily activities, their families, and their lives. I am encouraged by the initial clinical results from inCVAX.”

XIAOSONG LI, M.D. & PH. D.

BEIJING,P.R.CHINA

CAMPAIGN DRUG THERAPYYOUR DONATION

CLINICAL SITES

A VISION FULFILLED

“The ICanWin campaign is incredibly exciting. Thanks to the generosity of donors, and thanks to the partnership support from Immunophotonics, patients will be able to receive this investigational, innovative therapy in a compassionate use setting. We intend to collect additional information on the inCVAX approach, which is necessary to advance our research while trying to help late-stage cancer patients.”

LARS THORSELIUS, M.D.

SWEDEN

PERU

“As we rely on patient information and experiences to understand this experimental therapy and its potential effects, we will document the compassionate use cases with the goal to help even more people in the years to come. This investigational, innovative technology offers new hope and promise to patients in need. Patients who receive this therapy through compassionate use will be selected in a safe and ethical manner.”

ENRIQUE FREITAS, M.D.

Your Donationthrough

Crowdfunding

Donated Therapy

Initial material and therapy will be donated by Immunophotonics.

Copyright 2015 © ICanWin